$96.87 $2.03 (2.1%)

08:00 PM EST on 02/18/20

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)

CAPS Rating: 3 out of 5

Current Price $96.87 Mkt Cap $3.2B
Open $0.00 P/E Ratio 0.00
Prev. Close $96.87 Div. (Yield) $0.00 (0.0%)
Daily Range $0.00 - $0.00 Volume 21
52-Wk Range $90.94 - $121.53 Avg. Daily Vol. 522,149

Caps

How do you think NASDAQ:ICPT will perform against the market?

Add Stock to CAPS Watchlist

All Players

88 Outperform
31 Underperform
 

All-Star Players

24 Outperform
5 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:ICPT Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

TMFUltraLong (98.49)
Submitted November 16, 2017

https://www.fool.com/investing/2017/10/30/3-reasons-ive-been-aggressively-buying-intercept-p.aspx

NewbiesRock (< 20)
Submitted February 18, 2014

I picked underperformed because the Intercept Molecule had some negative impact on cholesterol and it seems they didn't fix that problem yet. The FDA will probably want to look deeper into that. Furthermore another company that has a very good… More

NASDAQ:ICPT VS S&P 500 (SPY)

Fools bullish on NASDAQ:ICPT are also bullish on:

Fools bearish on NASDAQ:ICPT are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about ICPT.

Recs

0
Member Avatar odocoileus (29.12) Submitted: 1/30/2020 11:00:16 PM : Outperform Start Price: $124.46 NASDAQ:ICPT Score: -62.58

I think the market has been a little harsh on ICPT. Ocaliva is likely to get approved for fibrosis and is likely to get used for less advanced NASH as well. It is further likely to have about a year of exclusivity. I think that GNFT, MDGL, VKTX and others will catch up, and will produce safer and more effective drugs. When that happens, I'm out of ICPT. For now I'm in. I expect it to get to $120 on approval and $200 the first year of sales. At that point I expect catalysts from other companies to start making investors nervous. Me included.

Recs

0
Member Avatar clangmead (43.09) Submitted: 7/18/2019 9:03:29 AM : Outperform Start Price: $68.84 NASDAQ:ICPT Score: +24.34

NASH Fibrosis trials; NDA; MAA

Recs

0
Member Avatar Bigsef77 (67.36) Submitted: 2/19/2019 10:07:10 AM : Outperform Start Price: $62.44 NASDAQ:ICPT Score: +27.52

Intercept up 23% premarket on positive OCA data
Feb. 19, 2019 7:43 AM ET|About: Intercept Pharmaceuticals (ICPT)|By: Douglas W. House, SA News Editor

Intercept Pharmaceuticals (NASDAQ:ICPT) is up 23% premarket on light volume following its announcement of positive results from a Phase 3 clinical trial, REGENERATE, evaluating obeticholic acid (OCA) in patients with liver fibrosis (scarring) due to nonalcoholic steatohepatitis (NASH).

The study met one co-primary endpoint, a statistically significant proportion of patients achieving at least one stage improvement in fibrosis with no worsening of NASH at month 18 (p=0.0002), but failed to meet the other, the proportion of patients achieving NASH resolution with no worsening of liver fibrosis. The FDA agreed that only one endpoint needed to be met in order to be judged successful.

The data will be presented at the European Association for the Study of the Liver (EASL): International Liver Congress in Vienna April 10 - 14.

The company plans to file a U.S. marketing application in H2.

See all stocks on the move »

Leaderboard

Find the members with the highest scoring picks in ICPT.

Score Leader

alkusari

alkusari (< 20) Score: +443.87

The Score Leader is the player with the highest score across all their picks in ICPT.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
vzwatmrk < 20 1/10/2014 Underperform 5Y $455.50 -79.19% +83.57% +162.76 0 Comment
Halffrenzy 25.64 1/10/2014 Underperform 5Y $438.98 -78.41% +83.94% +162.35 0 Comment
jjc007007 62.67 2/5/2014 Underperform 5Y $296.00 -67.98% +91.97% +159.95 0 Comment
sinvestor 71.65 1/14/2014 Underperform 3M $361.00 -73.74% +84.82% +158.56 1 Comment
kevrose31 79.66 1/10/2014 Underperform 1Y $373.00 -74.59% +83.14% +157.73 0 Comment
NewbiesRock < 20 2/18/2014 Underperform 5Y $353.89 -73.21% +82.90% +156.12 4 Comments
kayakmastr 74.06 1/13/2014 Underperform 1Y $339.87 -72.11% +83.38% +155.49 0 Comment
alexeysm 45.00 1/13/2014 Underperform 1Y $339.87 -72.11% +83.38% +155.49 0 Comment
Figgie27 < 20 1/13/2014 Underperform 3M $339.87 -72.11% +83.38% +155.49 0 Comment
gillet01 < 20 4/7/2014 Underperform 5Y $298.86 -68.28% +82.22% +150.50 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for ICPT.